ReviewJournal of thoracic disease2026
Pulmonary hypertension following lung transplant: a systematic review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-lung-transplant development of pulmonary hypertension (PH) is an increasingly recognized disease process with limited data regarding its etiologies and clinical course. We performed a systematic review to evaluate reported causes and patterns of PH following lung transplantation. Methods: This systematic review was registered with PROSPERO (CRD42025649383) and conducted according to PRISMA guidelines. A comprehensive search strategy was developed with a medical librarian and applied to MEDLINE (Ovid), Embase (Ovid), and the Cochrane Library. Studies were screened and managed using Covidence. Two reviewers independently screened titles, abstracts, and full texts, with disagreements resolved by consensus or a third reviewer. Eligible studies included case reports, retrospective or cohort studies, randomized controlled trials, and conference abstracts reporting post-lung-transplant PH with defined diagnostic criteria and plausible etiology. Studies without full text or sufficient data, non-original analyses, animal models, or non-English articles were excluded. Data were extracted using standardized forms, and risk of bias was assessed using the Newcastle-Ottawa Scale. Results: Fifteen studies met the inclusion criteria, including 12 case reports and 3 retrospective cohort studies, encompassing 223 patients. The most common etiology was chronic lung allograft dysfunction (CLAD), particularly bronchiolitis obliterans syndrome (BOS), accounting for 63% of cases. Other etiologies included vascular or anastomotic complications, recurrence of idiopathic pulmonary arterial hypertension, and recurrent thromboembolic disease. Conclusions: Post-lung-transplant PH most frequently occurs in association with CLAD/BOS. Prospective longitudinal studies are needed to better define the temporal relationship between CLAD/BOS and PH and to inform surveillance and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.